Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 21

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 21
---
 with a significant build-up of inventory in the Chinese market. Given that the Chinese market (and the broader economy) was not improving rapidly, there was risk that STAA might take longer to see those inventory levels improve and thus be able to sell through new product.” BTIG 8.5.25 “We sympathize with STAA, as it is forced to navigate a challenging environment, but visibility in China remains very low, with inventory dynamics further muddying the picture and making calling the bottom a challenging endeavor.” Morgan Stanley 2.12.25 “STAA shares have faced pressure over the last several quarters from a deteriorating China macroeconomic environment, but investor fears likely are now ratcheting higher due to new developments related to elevated inventory levels in China with the company’s distributors.” Stifel 2.12.25 Note: Permission to use quotations neither sought nor obtained. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR’s Independent and Experienced Board Conducted a Thoughtful Evaluation of Strategic Alternatives and Negotiated Favorable Terms that Maximize Value for STAAR Stockholders EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Negotiations overseen by STAAR’s independent and experienced board Stephen C. Farrell Chief Executive Officer since 2025; Director since 2016 20+ years executive leadership, operating, financial, governance, and global health care experience Former CEO and a member of the Board of Convey Health Solutions; Former CFO of Stream Global Services; Former CFO, COO, and President at PolyMedica Corporation Former member of the Board of Lineage Cell Therapeutics; previously on Board of Questcor Pharmaceuticals (NASDAQ: QCOR) Wei Jiang Director since 2024, Interim Strategic APAC Advisor since April 2025 25+ years pharmaceutical and medical device industry experience and extensive expertise in Asian markets Former EVP and President, Bayer Pharmaceuticals Region China & APAC; Former President, Bayer Group Greater China Region; Former SVP, China operations at AstraZeneca; Former Marketing Director, China Operations at Eli Lilly & Company Member of the Board of Waters Corporation (NYSE: WAT) Lilian Y. Zhou Chair, Audit Committee; Independent Director since 2023 20+ years of capital allocation, finance, governance experience, and global investor perspective Founded Y